Enhancement of Mucosal Defence by Prostaglandins. Rationale and Clinical Experience in Ulcer Disease

Abstract

In summary, the clinical relevance of enhancing gastric mucosal defence by PGs has not been established. The present evidence indicates that antisecretory doses of some synthetic PGE analogues may prove to be yet another beneficial approach to drug treatment in some aspects of peptic ulcer disease. However, there is no clinical evidence that they are superior to conventional ulcer healing agents, which are also ineffective in gastrointestinal tract bleeding – and ‘it is difficult to see how they are likely to threaten the therapeutic hegemony of cimetidine and ranitidine’ (3).